Everest Medicines to Remove "B" Marker from Stock Code on May 2, 2025
April 28, 2025 | 08:00
The regulatory milestone signals Everest Medicines' growing financial maturity and market confidence.
Everest Medicines Gets “B” Marker Removed from HKEX Listing Code
April 22, 2025 | 10:08
Everest marks a new chapter in market confidence as Hong Kong Exchange grants removal of its “B” designation.
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
March 24, 2025 | 06:30
Everest Medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine.
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
February 26, 2025 | 06:45
Everest Medicines, today announced the presentation of maintenance data from its multi-center Phase III clinical study of etrasimod (VELSIPITY®) in Asia at the 20th European Crohn's and Colitis Organization Congress (ECCO 2025).
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong
December 02, 2024 | 06:40
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics.
Everest Medicines announces the launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area
October 25, 2024 | 06:40
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy.
Everest medicines announces Taiwan TFDA approval of NEFECON® for the treatment of Primary IgA Nephropathy
October 21, 2024 | 06:40
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration has approved NEFECON® indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy who are at risk for disease progression".
Latest News
Mobile Version